Clinical implications of the p53 gene

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 285-301

  Sidransky, David ^a   Hollstein, Monica ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cell cycle; Clonality; Molecular diagnostics; Mutation

Indexed keywords

PROTEIN P53;

CANCER; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CELL GROWTH; DNA SYNTHESIS; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; HOMEOSTASIS; HUMANS; NEOPLASMS; POINT MUTATION; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029996069     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.285     Document Type: Review

References (89)

1. Lane DP, Crawford LV. 1979. T antigen is bound to a hostprotein in SV40-transformed cells. Nature 278:261-63
2. Linzer DI, Levine AJ. 1979. Characterization of a 54-Kdalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52
3. Volgelstein B, Kinzler KW. 1992. p53 function and dysfunction. Cell 70:523-26
4. Baker SJ, Markowitz S, Fearon ER, et al. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-15
5. Lane DP. 1992. p53, guardian of the genome. Nature 358:15-16
6. Wang XW, Yeh H, Schaeffer L, et al. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:188-95
7. El-Deiry WS, Tokino T, Velculescu VE, et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-25
8. Harper JW, Adami GR, Wei N, et al. 1993. The P21Cdk-interacting protein CIP1 is a potent inhibitor of Glcyclin-dependent kinases. Cell 75:805-16
9. Xiong Y, Hannon GJ, Zhang H, et al. 1993. p21 Is auniversal inhibitor of cyclin kinases. Nature 366:701-7
10. Qin X-Q, Livingston DM, Ewen M, et al. 1995. The transcription factor E2F-1 is a downstream target of RB action. Mol. Cell. Biol. 15:742-55
11. Chen J, Jackson MW, Kirschner MW, et al. 1995. Separate domains of p21 involved in the inhibition of CDK kinase and PCNA. Nature 374:386-88
12. Flores-Rozas H, Kelman Z, Dean FB, et al. 1994.Cdk-interacting protein 1 directly binds with proliferating cellnuclear antigen and inhibits DNA polymerase (Holoenzyme). Proc. Natl. Acad. Sci. USA 91: 8655-59
13. Waga S, Hannon GJ, Beach D, Stillman B. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-78
14. CIP1 in muscle and other terminally differentiating cells. Science 267:1024-26
15. Michieli P, Chedid M, Lin D, et al. 1994. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:3391-95
16. Macleod KF, Sherry N, Hannon G, et al. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev. 9:935-44
17. Smith ML, Chen I-T, Zhan Q, et al. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-80
18. Chen C-Y, Oliner JD, Zahn Q, et al. 1994. Interactions between p53 and MDM-2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 91:2684-88
19. Momand J, Zambetti GP, Olson DC, et al. 1992. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-45
20. Steller H. 1995. Mechanisms and genes of cellular suicide. Science 267:1445-49
21. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-99
22. Fisher DE. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell 78:539-42
23. Hainaut P, Milner J. 1993. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:4469-73
24. Maxwell SA, Roth JA. 1994. Posttranslational regulation of p53 tumor suppressor protein function. Crit. Rev. Oncog. 5:23-57
25. Lee S, Elenbaas B, Levine A, Griffith J, 1995. p53 and its 14 Kda C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-20
26. Jayaraman J, Prives C. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-29
27. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89: 7491-95
28. Livingstone LR, White A, Sprouse J, et al. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-35
29. Iskizaka Y, Chernov MV, Burns C, Stark GR. 1995. p53-dependent growth arrest of REF52 cells containing newly amplified DNA. Proc. Natl. Acad. Sci. USA 892: 3224-28
30. Yin YX, Tainsky MA, Bischoff FZ, et al. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplificaton in cells with mutant p53 alleles. Cell 70: 937-48
31. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-78
32. Prives C. 1994. How loops, sheets, and helices help us to understand p53. Cell 78: 543-46
33. Harvey M, Vogel H, Morris D, et al. 1995. A mutant P53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:305-11
34. Hann BC, Lane DP. 1995. The dominating effect of mutant p53. Nat. Genet. 9:221-22
35. Malkin D. 1994. Germline p53 mutations and heritable cancer. Annu. Rev. Genet. 28: 443-65
36. Hollstein M, Rice K, Greenblatt MS, et al. 1994. Data base of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551-55
37. Dean M. 1995. Resolving DNA mutations. Nat.Genet. 9:103-5
38. Wynford-Thomas D. 1992. p53 in tumour pathology: can we trust immunocytochemistry? J. Pathol. 166:329-30
39. Hall PA, Lane DP. 1994. p53 in tumour pathology: can we trust immunohistochemistry? Revisited. J. Pathol. 172:1-4
40. Baas IO, Mulder J-WR, Offerhaus GJA, et al. 1994. An evalution of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J.Pathol. 172:5-12
41. Flaman JM, Frebourg T, Moreau V, et al. 1995. A simple p53 functional assay for screening cell lines, blood and tumors. Proc. Natl. Acad. Sci. USA 32:3963-67
42. Brash DE, Rudolph JA, Simon JA, et al. 1991. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 88:10124-28
43. Cooper DN, Krawczak M. 1990. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and prediction. Hum. Genet. 85: 55-74
44. Brennan JA, Boyle JO, Koch WM, et al. 1995. Association between cigarette smoking and mutation of the p53 gene in head and neck squamous carcinoma. N. Engl. J. Med. 332:712-17
45. Montesano R, Kirby GM. 1994. Chemical carcinogens in human liver cancer. In Primary Liver Cancer: Etiological and Progression Factors, ed. C Brechot. Boca Raton, FL: CRC
46. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-67
47. Baker SJ, Preisinger AC. 1990. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50:7717-22
48. Sidransky D, Mikkelsan T, Cavenee W, Vogelstein B. 1992. Clonal expansion of p53 mutant cells leads to histologic progression in astrocytoma. Nature 335: 841-42
49. Boyle JO, Koch W, Hruban RH, et al. 1993. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53:4477-80
50. Kastan MB, Onyekwere O, Sidransky D, et al. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-11
51. Wada H, Asada M, Nakazawa S, et al. 1994. Clonal expansion of p53 mutant cells in leukemia progression in vitro. N. Engl. J. Med. 8:53-59
52. Kern SE, Fearon ER, Tersmette KW, et al. 1989. Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 261:3099-3103
53. Zeng ZS, Sarkis AS, Zhang ZF, et al. 1994. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J. Clin. Oncol. 12:2043-50
54. Mitsudomi T, Oyama T, Kusano T, et al. 1993. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85:2018-23
55. Esrig D, Elmajian D, Groshen S, et al. 1994. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331:1259-64
56. Faille A, De Cremoux P, Extra JM, et al. 1994. p53mutations and overexpression in locally advanced breast cancers. Br. J. Cancer 69:1145-50
57. Rosen PP, Lesser ML, Arroyo CD, et al. 1995. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J. Clin. Oncol. 13: 821-30
58. Visakorpi T, Kallioniemi OP, Heikkinen A, et al. 1992. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 84:883-87
59. Mok CH, Tsao SW, Knapp RC, et al. 1992. Unifocal origin ofadvanced human epithelial overian carcinoma. Cancer Res. 52: 5119-22
60. Chung KY, Mukhopadhyay T, Kim J, et al. 1993. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestivetract. Cancer Res. 53: 1676-83
61. Leach FS, Tokino T, Meltzer P, et al. 1993. p53 mutationand MDM-2 amplification in human soft tissue sarcomas. Cancer Res. 53:2231-34
62. Werness B, Levine A, Howley P. 1990. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 248:76-79
63. Barbosa M, Schlegel R. 1989. The E6 and E7 genes of HPV 18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 4: 1529-32
64. Scheffner M, Werness BA, Huibregtse JM, et al. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-36
65. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505
66. Kessis TD, Slebos RJ, Nelson WG, et al. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988-92
67. Howley PM. 1991. Role of the human papillomaviruses in human cancer. Cancer Res. 51(Suppl. 18):S5019-22
68. Sidransky D. 1995. Molecular markers in cancer diagnosis. J. Natl. Cancer Inst. 17: 17-29
69. Sidransky D, Von Eschenbach A, Tsai YC, et al. 1991. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-9
70. Hruban RH, van der Riet P, Erozan YS, Sidransky D. 1994. Molecular biology and the early detection of carcinoma of the bladder: the case of Hubert Horatio Humphrey. N. Engl. J. Med. 330:1276-78
71. Mao L, Hruban RH, Boyle JO, et al. 1994. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54:1634-37
72. Brennan JA, Mao L, Hruban RH, et al. 1995. Molecular assessment of histopathologic staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332:429-35
73. Rainov NG, Dobberstein K-U, Fittkau M, et al. 1995. Absence of p53 autoantibodies in sera from glioma patients. Clin. Cancer Res. 1:775-81
74. Angelopoulou K, Diamandis EP, Sutherland DJA, et al. 1994. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer 58:480-87
75. Lubin R, Schlichtholz B, Bengoufa D, et al. 1993. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure and protein surface. Cancer Res. 53:5872-76
76. Davidoff AM, Inglehart JD, Marks JR. 1992. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA 89: 3439-42
77. Winter SF, Minna JD, Johnson BE, et al. 1992. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52:4168-74
78. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP. 1994. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A0201 peptide consensus motif. Cancer Res. 54:1175-77
79. Lubin R, Zalcman G, Bouchei L, et al. 1995. Serum p53 antibodies as early markers of lung cancer. Nat. Med. 11:701-2
80. Trivers GE, Cawley HL, DeBenedetti WMG, et al. 1995. Anti-p53 antibodies in the serum of workers occupationally exposed to vinyl chloride. J. Natl. Cancer Inst. In press
81. Peyrat J-P, Bonneterre J, Lubin R, et al. 1995. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancer 345:621-22
82. Winter SF, Sekido Y, Minna JD, et al. 1993. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: assocation with improved survival. J.Natl. Cancer Inst. 85:2012-18
83. Kastan MB, Onyekwere O, Sidransky D, et al. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-11
84. Lowe SW, Ruley HE, Jacks T, et al. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-67
85. Dulic V, Kaufmann WK, Wilson SJ, et al. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-23
86. Van Meir EG, Polverini PJ, Chazin VR, et al. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat. Genet. 8:171-76
87. Dameron KM, Volpert OV, Tainsky MA, Bouck N. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-84
88. Hartwell LH, Kastan MB. 1994. Cell cycle control and cancer. Science 266:1821-28
89. Brachman DG, Beckett M, Graves D, et al. 1993. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 53:3667-69